Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Neurology Undisclosed
United Kingdom 
Details:
The funding will be used to advance Locate Bio’s proprietary pipeline, including its lead product called LDGraft, a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.
Lead Product(s): rhBMP-2
Therapeutic Area: Neurology Product Name: LDGraft
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Mercia Asset Management
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 03, 2021
Details:
Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.
Lead Product(s): DNA plasmids
Therapeutic Area: Neurology Product Name: CG01
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CombiGene AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 13, 2020
Details:
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.
Lead Product(s): CG01
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
